Aripiprazole

• atypical antipsychotic.
• schizophrenia and bipolar disorder M/D
Monotherapy, Adjunt to lithium or valproate,
Adjunct to antidepressants, Agitation..INJ
• F: 87%, T-half: 75 hours (AM 94 hours)
• M: Liver (mostly via CYP3A4 and 2D6)
• D2 partial agonism, not D2 antagonism
• partial 5-HT1A agonist
• 5-HT2A antagonist
• lower risk of EPS and hyperprolactinemia than
other antipsychotics
• Positive symptoms of schizophrenia might be
the result of an overactivation of the
mesolimbic pathway
• Aripiprazole decrease activity in the
mesolimbic pathway through partial D2
agonism
• negative and cognitive symptoms
hypofunction of dopaminergic
neurotransmission in the mesocortical
pathway
• Aripiprazole increase dopaminergic activity
from a subnormal level to normal activity in
the mesocortical pathway
 ZIPRASIDONE
• atypical antipsychotic
• schizophrenia as well as acute mania
• M: Hepatic F: 60% (oral); 100% (IM)
• combination of dopamine type 2 (D2) and
serotonin type 2 (5HT2) antagonism
• H1- somonolesence
• A-1- orthostatic hypertension
• QT prolongation
 questions
• Classify antipsychotic drugs
• Compare typical & atypical antipsychotic
drugs = 6 marks
• Write briefly
- Aripiprazole
- Atypical antipsychotics